Celltrion Pharm Posts Q2 Sales of 131.3 Billion KRW and Operating Profit of 15.5 Billion KRW

Sales Up 12%, Operating Profit Surges 64.8% Year-on-Year
Celltrion Pharm Achieves Record Second-Quarter Results Driven by Robust Growth Across Key Divisions

On August 14, Celltrion Pharm announced through its management performance disclosure that it recorded sales of 131.3 billion KRW in the second quarter of this year. This figure represents a 12.1% increase compared to the same period last year, marking the highest second-quarter sales in the company's history.

Operating profit reached 15.5 billion KRW, a 64.8% increase year-on-year, while the operating margin also rose by more than 4 percentage points to 11.8%. For the first half of the year, cumulative sales amounted to 243.8 billion KRW and operating profit to 26.2 billion KRW, representing year-on-year growth of 13.9% and 100.3%, respectively.

First, the chemical business division generated 66.3 billion KRW in sales. The flagship liver supplement “Godex” posted 16 billion KRW in sales, up 6.9% year-on-year, while the hypertension treatment “Dilatrend Tab.” achieved 15.1 billion KRW in sales, a 7% increase, both contributing to the overall growth. The diabetes treatment “Nesina,” which has completed internalized production, saw significant growth with sales of 6.4 billion KRW, up 65.7% year-on-year. In addition, the diabetes treatment “Actos” and the hypertension treatment “Edarbi” recorded sales of approximately 1.8 billion KRW and 2.7 billion KRW, respectively.

In the biosimilar business division, sales reached 32.5 billion KRW, a 58.3% increase compared to the same period last year, maintaining robust growth. Among these, the autoimmune disease treatment “Remsima,” the breast and gastric cancer treatment “Herzuma,” and the blood cancer treatment “Truxima” together achieved total sales of 18.8 billion KRW. The autoimmune disease treatment “Yuflyma” posted sales of 1.8 billion KRW, up 129.4% year-on-year, and the anticancer agent “Begzelma” recorded sales of 2 billion KRW, up 125.5% year-on-year.

The newly launched biosimilar products this year also contributed to sales growth. With the full-scale sales of new biosimilars such as the autoimmune disease treatment “Stekima,” the ophthalmic disease treatment “Eydenzelt,” the allergic asthma treatment “Omriclo,” and the bone disease treatment “Stovoclo-Osenbelt,” total sales from these new products reached 9.7 billion KRW.

In the contract manufacturing division, the commercial production of PFS (Prefilled Syringe) products such as the autoimmune disease treatments “Remsima SC” and “Yuflyma” increased, resulting in sales of 23.2 billion KRW, up 24.6% year-on-year. With global demand for major SC products rising rapidly, continued growth is expected in the contract manufacturing sector as well.

Celltrion Pharm plans to strengthen its market competitiveness by pursuing differentiated strategies, including increasing biosimilar product output, enhancing the competitiveness of internalized products, and expanding contract manufacturing, while also boosting sales growth and profitability and actively investing in research and development (R&D).

A Celltrion Pharm representative stated, “We achieved record second-quarter results thanks to the solid growth of existing products and the full-scale launch of new products,” adding, “We will continue to do our best to maintain steady performance by reinforcing the sales competitiveness of our main products based on a stable production foundation.”